Factory Supply Vonoprazan Fumarate CAS: 1260141-27-2 In Stock

Vonoprazan fumarate CAS:1260141-27-2 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Vonoprazan Fumarate has a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding the potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan provides a strong and sustained acid section inhibitory effect. It is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis Vonoprazan fumarate CAS:1260141-27-2, the fumarate salt form of vonoprazan, is a pyrrole derivative and reversible potassium-competitive acid blocker (P-CAB), with potential antacid activity. Upon administration, vonoprazan specifically and competitively binds to the gastric hydrogen-potassium ATPase (H+/K+ ATPase) proton pump at or, more likely, near its potassium ion (K+) binding site and sterically inhibits K+ binding. This blocks the activation of the H+/K+ ATPase by K+, inhibits the proton pump and prevents gastric acid secretion, thereby lowering gastric acid levels. Check for active clinical trials using this agent. Vonoprazan fumarate CAS:1260141-27-2 is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February, 2015. It can be used for the treatment of gastroduodenal ulcer, reflux esophagitis, and for some drug-induced peptic ulcers. It can be combined with other antibiotics for the eradication of Helicobacter pylori.
Chat Now

Product Details

--2_01.png

Product Description

Name

Factory supply Vonoprazan fumarate CAS: 1260141-27-2 in stock

Other name

Vonoprazan; TAK-438; Takecab; 881681-01-2 ; 1-[5-(2-Fluorophenyl)-1-(3-pyridinylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (2E)-2-butenedioate

CAS

1260141-27-2

Applications

API

Appearance

White to off-white powder

  Vonoprazan fumarate CAS:1260141-27-2  is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Vonoprazan Fumarate has a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding the potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan provides a strong and sustained acid section inhibitory effect. It is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis.

  Vonoprazan fumarate CAS:1260141-27-2, the fumarate salt form of vonoprazan, is a pyrrole derivative and reversible potassium-competitive acid blocker (P-CAB), with potential antacid activity. Upon administration, vonoprazan specifically and competitively binds to the gastric hydrogen-potassium ATPase (H+/K+ ATPase) proton pump at or, more likely, near its potassium ion (K+) binding site and sterically inhibits K+ binding. This blocks the activation of the H+/K+ ATPase by K+, inhibits the proton pump and prevents gastric acid secretion, thereby lowering gastric acid levels. Check for active clinical trials using this agent.

1260141-27-2.jpg


Hot Tags: factory supply vonoprazan fumarate cas: 1260141-27-2 in stock, China, suppliers, manufacturers, factory, wholesale, bulk

Inquiry

You Might Also Like